Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theralase Technologies Inc. V.TLT.W


Primary Symbol: V.TLT Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

Recent & Breaking News (TSXV:TLT)

Theralase Announces Settlement Agreement with Ontario Securities Commission

Filing Services Canada February 26, 2018

Theralase Anti-Cancer Technology Treats Sixth Patient for Bladder Cancer

Filing Services Canada February 9, 2018

Correcting and Replacing: Theralase Anti-Cancer Technology Used to Treat Fifth Patient for Bladder Cancer

Filing Services Canada January 18, 2018

Theralase Anti-Cancer Technology Used to Treat Fifth Patient for Bladder Cancer

Filing Services Canada January 18, 2018

Theralase Optimizes Delivery Schedule of Anti-Cancer Vaccine in Destruction of Brain Cancer

Filing Services Canada January 17, 2018

Theralase Discovers Theralase(R) Cold Laser Therapy Enhances Cancer Destruction for Standard Cancer Treatments

Filing Services Canada November 30, 2017

Theralase Increases Revenue 12% for 3Q2017 Financial Statements

Filing Services Canada November 29, 2017

Theralase Therapeutic Laser Technology Enhances Cancer Destruction

Filing Services Canada November 27, 2017

Theralase Anti-Cancer Vaccine Validated in Colorectal Cancer

Filing Services Canada November 22, 2017

Theralase Demonstrates 24 Months Stability of Second Clinical Batch of Lead Anti-Cancer Drug

Filing Services Canada November 21, 2017

Theralase Discovers New Anti-Cancer Vaccine

Filing Services Canada November 20, 2017

IIROC Trading Resumption - TLT

Canada NewsWire November 13, 2017

IIROC Trading Halt - TLT

Canada NewsWire November 13, 2017

IIROC Trade Halt - Theralase Technologies Inc.

Newsfile November 13, 2017

Theralase Provides Interim Data Analysis on Anti-Cancer Treatment for First Four Patients Treated

Filing Services Canada November 8, 2017

Theralase Anti-Cancer Drugs Independently Reviewed

Filing Services Canada October 31, 2017

Theralase Research to be Presented at International Conference

Filing Services Canada October 30, 2017

Theralase Lead Anti-Cancer Drug Effective in the Destruction of Brain Cancer when Activated by X-Rays

Filing Services Canada September 25, 2017

Theralase Demonstrates 24 Month Stability of Lead Anti-Cancer Drug

Filing Services Canada September 18, 2017

Theralase Demonstrates Increased Efficacy for Latest Anti-Cancer Drug

Filing Services Canada September 12, 2017